Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Long-Term Deferred Tax (2018 - 2021)

Cytosorbents' Long-Term Deferred Tax history spans 3 years, with the latest figure at $4.1 million for Q4 2021.

  • Quarterly results put Long-Term Deferred Tax at $4.1 million for Q4 2021, up 843.05% from a year ago — trailing twelve months through Dec 2021 was $4.1 million (up 843.05% YoY), and the annual figure for FY2021 was $4.1 million, up 843.05%.
  • Long-Term Deferred Tax for Q4 2021 was $4.1 million at Cytosorbents, up from $431490.0 in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $4.1 million in Q4 2021 to a low of $21856.0 in Q4 2018.
  • The 3-year median for Long-Term Deferred Tax is $431490.0 (2020), against an average of $1.5 million.
  • Peak annual rise in Long-Term Deferred Tax hit 843.05% in 2021, while the deepest fall reached 843.05% in 2021.
  • Year by year, Long-Term Deferred Tax stood at $21856.0 in 2018, then skyrocketed by 1874.24% to $431490.0 in 2020, then surged by 843.05% to $4.1 million in 2021.
  • According to Business Quant data, Long-Term Deferred Tax over the past three periods came in at $4.1 million, $431490.0, and $21856.0 for Q4 2021, Q4 2020, and Q4 2018 respectively.